Comparison between subcutaneous and intravenous interleukin‐2 treatment in HIV disease
- 1 September 1998
- journal article
- Published by Wiley in Journal of Internal Medicine
- Vol. 244 (3) , 235-240
- https://doi.org/10.1046/j.1365-2796.1998.00365.x
Abstract
Therapy of HIV-infection using intravenous interleukin-2 (IL-2) is known to be effective in terms of increasing CD4-counts but is associated with significant side-effects and hospitalization. However, the combination with protease-inhibitor therapy has not been tested yet. The aim of the present study was to investigate the safety and efficacy of intravenous vs. subcutaneous IL-2 regimes using 9 Mio I.U. of IL-2, in combination with protease-inhibitor therapy. All patients were treated with a combination of two reverse transcriptase inhibitors and a protease-inhibitor prior to IL-2 administration for at least 6 weeks. Ten patients were assigned to the intravenous IL-2 group (group A). 10 to the subcutaneous group (group B). In both treatment groups, CD4 count significantly increased shortly after the end of therapy (group A: 223% over baseline [day 7]; group B: 264% over baseline [day 7]). During the follow-up CD4 counts slowly decreased thereafter but remained above baseline 3 months following IL-2 treatment. The CD8 lymphocytes showed a similar but less pronounced pattern with a maximum at day 7 (group A: 116% over baseline, group B: 158% over baseline) and reached baseline earlier in the follow-up-period. Altogether the CD4/CD8-ratio was elevated through long periods on follow-up. Throughout follow-up, there were no apparent changes in viral load during IL-2 therapy in either groups. IL-2 therapy was administered for a mean time of 4.2+/-0.1 days in the intravenous group and of 4.8+/-0.1 days in the subcutaneous group until therapy was terminated at day 5 or due to side-effects. Only 1/10 patients completed the 5-day course of intravenous therapy in contrast to 6/10 in the subcutaneous group. Subcutaneous interleukin-2 using 9 Mio IU day(-1) in combination with protease-inhibitors showed equal efficacy as intravenous therapy and was associated with less side-effects.Keywords
This publication has 13 references indexed in Scilit:
- Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral TherapyNew England Journal of Medicine, 1997
- Controlled Trial of Interleukin-2 Infusions in Patients Infected with the Human Immunodeficiency VirusNew England Journal of Medicine, 1996
- A 24-week open-label Phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)AIDS, 1996
- Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and ZalcitabineNew England Journal of Medicine, 1996
- Alterations in the Immune Response of Human Immunodeficiency Virus (HIV)-Infected Subjects Treated with an HIV-Specific Protease Inhibitor, RitonavirThe Journal of Infectious Diseases, 1996
- Increases in CD4 T Lymphocytes with Intermittent Courses of Interleukin-2 in Patients with Human Immunodeficiency Virus Infection — A Preliminary StudyNew England Journal of Medicine, 1995
- Cytokine Patterns During the Progression to AIDSScience, 1994
- A Phase I Study of Interferon-α2b in Combination with Interleukin-2 in Patients with Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 1994
- Efficacy of Low Doses of the Polyethylene Glycol Derivative of Interleukin-2 in Modulating the Immune Response of Patients with Human Immunodeficiency Virus Type 1 InfectionThe Journal of Infectious Diseases, 1993
- Interleukin-2: Inception, Impact, and ImplicationsScience, 1988